Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Lysarc
Sponsor

Lysarc

France 2d Lyon Sud Batiment, 69495 Pierre Benite, France

About the sponsor

Research activity includes diffuse large B-cell lymphoma, relapsed/refractory aggressive B-NHL, primary diffuse large B-cell lymphoma of the CNS, and other high-risk B-cell malignancies, with interest in both newly diagnosed and relapsed settings.

  • CAR T-cell therapy
  • Bispecific antibodies
  • Anti-CD19 and anti-CD20 approaches
  • Lenalidomide-based combinations

Additional work spans molecular response, complete response, and progression-free survival in aggressive lymphoma subtypes.

About Specializations

Lysarc runs clinical trials in conditions such as Diffuse large B-cell lymphoma, Peripheral T-cell lymphoma unspecified, Mantle cell lymphoma, B-cell lymphoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

16 clinical trials

Peripheral T-cell lymphoma unspecified+1

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Lysarc

Central nervous system lymphoma+1

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Lysarc

Mantle cell lymphoma

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Lysarc

B-cell lymphoma+1

Recruiting
Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:Lysarc

Diffuse large B-cell lymphoma

Recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Lysarc

Peripheral T-cell lymphoma unspecified

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Brentuximab Vedotin
  • Sponsor:Lysarc

Marginal zone lymphoma refractory

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Lysarc

Diffuse large B-cell lymphoma

Not yet recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Lysarc

Angioimmunoblastic T-cell lymphoma refractory

Not recruiting
Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Lysarc

Peripheral T-cell lymphoma unspecified

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Lysarc

Diffuse large B-cell lymphoma+1

Not recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Lysarc

Follicular lymphoma

Not recruiting
Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Lysarc

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).